CirTran Corporation reported strong operational progress for the third quarter of 2026, with net sales rising 47.9% to $663,511. The company successfully narrowed its operating loss by 71.8% to $46,963 through disciplined cost reductions, while year-to-date net income reached $1,827,615, or $0.37 per share, bolstered by income from discontinued operations.
The company's Q3 2026 results, published November 16, 2026, show hard improvements: net sales up 47.9% to $663,511, nine-month sales up 178% to $2,996,530, operating expenses down 19.5% in Q3, and the continuing-operations loss narrowed 32.9% to $272,618. Year-to-date the company swung to an operating income of $149,787 and net income of $1,827,615 ($0.37 per share), a clear beat versus the prior-year loss. For a company of this size these percentages are material and should support the share price, though thin OTC liquidity can amplify or mute the reaction.
- ▲ Q3 2026 net sales up 47.9% to $663,511; nine-month sales up 178% to $2,996,530
- ▲ Q3 operating loss narrowed 71.8% to $46,963; nine-month continuing-operations loss cut 58.6% to $433,872
- ▼ Q3 still shows a net loss from continuing operations of $272,618; profitability rests largely on $2,261,487 of income from discontinued operations
- ▼ Management notes Q3 reflects 'seasonal moderation' from a record first half, so momentum may slow